Published in:
01-12-2015
Potential Role of CT Metrics in Chronic Obstructive Pulmonary Disease with Pulmonary Hypertension
Authors:
Katsutoshi Ando, Hiroshi Kuraishi, Tetsutaro Nagaoka, Takeo Tsutsumi, Yoshito Hoshika, Toru Kimura, Hiroki Ienaga, Yoshiteru Morio, Kazuhisa Takahashi
Published in:
Lung
|
Issue 6/2015
Login to get access
Abstract
Purpose
Recent imaging studies demonstrated the usefulness of quantitative computed tomographic (CT) analysis assessing pulmonary hypertension (PH) in patients with chronic obstructive lung disease (COPD–PH). The aim of this study was to investigate whether it would be also valuable for predicting and evaluating the effect of pulmonary vasodilators in patients with COPD–PH.
Methods
We analyzed a correlation between the extent of cystic destruction (LAA%) and total cross-sectional areas of small pulmonary vessels less than 5 mm2 (%CSA <5) in many CT slices from each of four COPD–PH patients before and after the initiation of pulmonary vasodilator. To evaluate those generalized data from patients with COPD, we evaluated multiple slices from 42 patients whose PH was not clinically suspicious. We also selected five PH patients with idiopathic interstitial pneumonia (IIP–PH) and analyzed serial changes of pulmonary artery enlargement (PA:A ratio).
Results
In 42 COPD patients without PH, LAA% had a statistically significant negative correlation with %CSA <5. However, three of four COPD–PH patients manifested no such correlation. In two patients, clinical findings were dramatically improved after the initiation of pulmonary vasodilator. Notably, LAA% and %CSA <5 in those patients correlated significantly after its treatment. In COPD–PH, the PA:A ratio was significantly decreased after the initiation of pulmonary vasodilator therapy (1.25 ± 0.13 vs. 1.13 ± 0.11, p = 0.019), but not in IIP–PH.
Conclusions
Our study demonstrates that the use of quantitative CT analysis is a plausible and beneficial tool for predicting and evaluating the effect of pulmonary vasodilators in patients with COPD–PH.